Centers for Disease Control. Summary of notifiable diseases, United States, 1991 . MMWR Morb Mortal Wkly Rep . 1991;;40:35-36, 57-63.
Varughese P. Incidence of pertussis in Canada . Can Med Assoc J . 1985;;132: 1041-1042.
Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children . Pediatrics . 1981;;68:650-659.
Centers for Disease Control and Prevention. Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use supplementary ACIP statement: recommendations of the Immunization Practices Advisory Committee . MMWR Morb Mortal Wkly Rep . 1992;;41(No.
Podda A, Nencioni L, Marsili I, et al. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa . Vaccine . 1991;;9:741-745.
Miller E, Ashworth LAE, Robinson A, Waight PA, Irons LI. Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens . Lancet . 1991;;337:70-73.
Blumberg DA, Mink CM, Cherry JD, et al. Comparison of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants . J Pediatr . 1991;;119:194-204.
Halperin SA, Barreto L, Friesen B, Meekison W. Immunogenicity of a five-component acellular pertussis vaccine in infants and young children . Arch Pediatr Adolesc Med . 1994;;148:495-502.
National Advisory Committee on Immunization. Pertussis vaccine . In: Canadian Immunization Guide . 3rd ed. Ottawa, Ontario: Health and Welfare, Canada; 1989;:78-83.
Committee on Infectious Diseases, American Academy of Pediatrics. Acellular pertussis vaccines: recommendations for use as the fourth and fifth doses . Pediatrics . 1992;;90:121-123.
Sekura R, Zhang Y, Roberson R, et al. Clinical, metabolic, and antibody responses of adult volunteers to an investigational vaccine composed of pertussis toxin inactivated by hydrogen peroxide . J Pediatr . 1988;;113:806-813.
Siber G, Thakrar N, Yancey B, et al. Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children . Vaccine . 1991;; 9:735-740.
Baker JD, Halperin SA, Edwards K, Miller B, Decker M, Stephens D. Antibody response to Bordetella pertussis antigens after immunization with American and Canadian whole-cell vaccines . J Pediatr . 1992;;121:523-527.
Blennow M, Granström M, Jäätmaa E, Olin P. Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial . Pediatrics . 1988;;82:293-299.